TY - JOUR
T1 - Estrogen-based hormone therapy in women with primary ovarian insufficiency
T2 - a systematic review
AU - Burgos, Nydia
AU - Cintron, Dahima
AU - Latortue-Albino, Paula
AU - Serrano, Valentina
AU - Rodriguez Gutierrez, Rene
AU - Faubion, Stephanie
AU - Spencer-Bonilla, Gabriela
AU - Erwin, Patricia J.
AU - Hassan Murad, Mohammad
N1 - Funding Information:
DC and GSB were supported by the CTSA Grant Number TL1 TR000137 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). GSB was also supported by grant number 3R01HL131535-01S1 from the National Heart Lung and Blood Institute (NHLBI). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH. Nydia Burgos and Dahima Cintron contributed equally to this work. S.F. is currently a consultant for Mithra Pharmaceuticals. The remaining authors declare that they have no competing interests.
Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
AB - Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
KW - Cardiovascular
KW - Estrogen
KW - Fracture
KW - Lipids
KW - Ovarian insufficiency
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85031904796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031904796&partnerID=8YFLogxK
U2 - 10.1007/s12020-017-1435-x
DO - 10.1007/s12020-017-1435-x
M3 - Article
C2 - 29039146
AN - SCOPUS:85031904796
SN - 1355-008X
VL - 58
SP - 413
EP - 425
JO - Endocrine
JF - Endocrine
IS - 3
ER -